International heart disease registry for amyloidosis
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with cardiac amyloidosis (either AL or ATTR type) by a doctor, based on standard tests like blood tests, heart imaging, or a biopsy.
- You need to have symptoms, ECG, echo, or MRI results that suggest the heart is involved with amyloidosis.
- If you have ATTR type, you must have either a positive bone scan (Perugini grade 2 or 3) or a positive scan (grade 1) plus a biopsy showing ATTR amyloid.
- If you have AL type, you need a positive blood test, a negative bone scan (grade 0), an MRI suggesting amyloidosis, and a biopsy showing AL amyloid.
- You must be willing and able to give informed consent (understand and agree to take part).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
This study is a registry that collects information from people with cardiac amyloidosis. It helps doctors learn more about the condition and how to better treat it.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
This study collects information from people with suspected or confirmed amyloidosis. The goal is to learn more about the condition and improve patient care.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.